Biophan Technologies to Present at California Nanotechnology Conference.Business Editors/Health/Medical Writers NanoSig Nano-Bio Forum ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 24, 2004 Biophan will be presenting at the NanoSig Nano-Bio Forum, taking place February 26, 2004 at the UCSD UCSD University of California, San Diego (La Jolla, California) UCSD User Centered System Design UCSD Urbana-Champaign Sanitary District (Illinois) UCSD Ultra Cool Sexy Dudes Connect Facility in La Jolla, CA Biophan Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ) announced today that it will present at NanoSig's Conference, "Big Business: Bridging Commercial Applications in Nano-Bio Technology," starting at 4:00 p.m. (PT) on Thursday, February 26, 2004. The conference features technology development at the interface of nanotechnology and biotechnology and is being held at the UCSD Connect facility in La Jolla, CA. Biophan is using nanomagnetic particle technologies as a solution to MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. image artifacts artifacts see specimen artifacts. and MRI heating of biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. devices, which keeps millions of people from benefiting from MRI scans. Biophan has demonstrated reduced image artifacts of implantable devices (such as pacemaker leads) and minimally invasive tools (such as guidewires and catheters) and reduced device heating using nanomagnetic thin film coatings. Biophan recently announced its new NanoView(TM) technology which will utilize nanomagnetic particles as contrast agents that preferentially bind to tissues of diagnostic interest, creating improved detail and contrast in images. NanoView is intended to improve signal intensity and permit the use of multiple markers. Biophan CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Michael Weiner will describe how Biophan learned about research being conducted at Alfred University by Professor Xingwu Wang, and decided to invest in developing this technology. Biophan is working with Dr. Wang's company, Nanoset, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , which was established to commercialize several of Dr. Wang's inventions. Nanoset has two issued U.S. patents, two more have been allowed and will issue soon, and another twelve are pending. Biophan holds the worldwide exclusive rights to these patents for all medical applications. Mr. Weiner will outline other nanotechnology capabilities that may soon impact the biomedical device industry. About Biophan Technologies Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI) equipment. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have four issued U.S. patents and over fifty patents pending, in areas including nanomagnetic particle coatings, radio frequency filters, polymer composites, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. About This Conference For more information on this conference, please visit http://www.nanoforums.org. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement: Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of the Company's MRI technologies; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion